Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 1Hypoxia 1Carcinoma, Hepatocellular 1

Interventions

Oxaliplatin 152Fluorouracil 137Gemcitabine 118Bevacizumab 116Leucovorin 106Specimen Handling 105Capecitabine 96pembrolizumab 90Magnetic Resonance Spectroscopy 83Nivolumab 79Cisplatin 79Irinotecan 71durvalumab 64Cetuximab 62Biopsy 61Paclitaxel 60130-nm albumin-bound paclitaxel 59Radiotherapy 46atezolizumab 45Albumin-Bound Paclitaxel 37Taxes 36Carboplatin 36Folfox protocol 35Drug Therapy 32Cyclophosphamide 30lenvatinib 29dehydroftorafur 29tislelizumab 27sintilimab 27Radiation 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Tirapazamine × Gastrointestinal × 90 days × Clear all
NCT02174549 2026-04-20

Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Teclison Ltd.

Phase 1/2 Recruiting
25 enrolled
EndocrineGastrointestinalNET

Hypoxia, Carcinoma, Hepatocellular, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡